Clinical Trial Detail

NCT ID NCT02060188
Title A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

colorectal cancer

Therapies

Nivolumab

Ipilimumab

Age Groups: adult

No variant requirements are available.